Gregson, JM, Freitag, DF, Surendran, P, Stitziel, NO, Chowdhury, R, Burgess, S, Kaptoge, S, Gao, P, Staley, JR, Willeit, P, Nielsen, SF, Caslake, M, Trompet, S, Polfus, LM, Kuulasmaa, K, Kontto, J, Perola, M, Blankenberg, S, Veronesi, G, Gianfagna, F, Männistö, S, Kimura, A, Lin, H, Reilly, DF, Gorski, M, Mijatovic, V, Munroe, PB, Ehret, GB, Thompson, A, Uria-Nickelsen, M, Malarstig, A, Dehghan, A, Vogt, TF, Sasaoka, T, Takeuchi, F, Kato, N, Yamada, Y, Kee, F, Müller-Nurasyid, M, Ferrières, J, Arveiler, D, Amouyel, P, Salomaa, V, Boerwinkle, E, Thompson, SG, Ford, I, Wouter Jukema, J, Sattar, N, Packard, CJ, Shafi Majumder, AA, Alam, DS, Deloukas, P, Schunkert, H, Samani, NJ, Kathiresan, S
, Nordestgaard, BG, Saleheen, D, Howson, JM, Di Angelantonio, E, Butterworth, AS & Danesh, J 2017, '
Genetic invalidation of Lp-PLA2 as a therapeutic target: Large-scale study of five functional Lp-PLA2-lowering alleles',
European Journal of Preventive Cardiology, bind 24, nr. 5, s. 492-504.
https://doi.org/10.1177/2047487316682186